Mr. Sieczkarek served as Chairman of the Board from April 2015 until March 2019 and served as Chief Executive Officer (“CEO”) from June 1, 2016 until September 28, 2018 (including serving as Interim President and CEO of NovaBay from November 2015 to May 31, 2016). Mr. Sieczkarek currently serves as chief executive officer of Fe3 Medical, Inc., a private company focused on developing a novel transdermal therapy for iron deficiency anemia, since 2015, and chief executive officer of MarkAnn Inc., LLC, a private real estate holding company. Mr. Sieczkarek has more than 37 years of leadership experience in the pharma, device and diagnostics industries and most recently served as chairman, president and chief executive officer of Solta from April 2016 until it was acquired by Valeant Pharmaceuticals International, Inc. in January 2014. Mr. Sieczkarek was also Lead Director of Solta for seven (7) years and served on the audit committee and as head of the compensation committee. Mr. Sieczkarek also served as president and chief executive officer of Conceptus from 2003 to 2011. Previously, Mr. Sieczkarek was senior vice president and president of Bausch & Lomb’s Americas Region, responsible for the commercial operation of all Bausch & Lomb businesses in the United States, Canada and Latin America. Mr. Sieczkarek joined Bausch & Lomb in 1995 as vice president and controller in the Personal Products division and also served as president of Europe, and a vice president in Corporate Business Development. Previously, Mr. Sieczkarek held an executive level position with KOS Pharmaceuticals, several Bristol Myers-Squibb subsidiaries and Sanofi Diagnostics Pasteur. Mr. Sieczkarek received an M.B.A. degree in Finance from Canisius College in Buffalo, New York, and a B.S. degree in Accounting from the State University of New York at Buffalo.
Paul E. Freiman
Mr. Freiman joined NovaBay’s Board in 2002 and has held various positions during his 17 year tenure at the Company, including Lead Independent Director, Chairman of the Compensation Committee, and since March 2019, Chairman of the Board. Paul E. Freiman currently serves as Chairman of Penwest Pharmaceutical Co., and serves on the boards of Calypte Biomedical Corporation, NeoPharm, Inc., Otsuka America Pharmaceuticals, Inc., and SciGen Ltd. Mr. Freiman was most recently the President and CEO of Neurobiological Technologies Inc. Prior to this role, he held the position of Chairman and CEO of Syntex Corporation, which was sold to The Roche Group for $5.3 billion during his tenure.
Mr. Freiman holds a B.S. degree in pharmacy from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy.
Mr. Li (LI Xinzhou) has served as a director of NovaBay since April 10, 2015. Mr. Li is Chairman and Executive Director of China Pioneer Pharma, the exclusive distributor of NovaBay’s NeutroPhase® Skin and Wound Cleanser in China and Southeast Asia, as well as NovaBay’s largest stockholder. Mr. Li previously served as the Board’s Asia-Pacific advisor for over two years. Mr. Li founded China Pioneer Pharma in July 1996, and is responsible for managing its operations and planning, and for formulating the company’s strategies. He has more than eighteen years of experience in the pharmaceutical services industry and has more than twenty years of experience in international trading and management. Prior to China Pioneer Pharma, Mr. Li worked at the Hainan branch of Sumitomo Corporation.
Mr. Li graduated from Jianghan Petroleum Normal School with a diploma in English and studied at the China Europe International Business School.
Ms. Maderis has served as a director of NovaBay since October 2010. Ms. Maderis is currently the President and CEO of Antiva Biosciences, Inc. since July 2015. Prior to joining Antiva, Ms. Maderis served as President and CEO of BayBio before its merger with California Healthcare Institute (CHI) in December of 2014. Ms. Maderis was previously President and CEO of FivePrime Therapeutics, Inc., a biotechnology company that is focused on the discovery and development of innovative protein and antibody drugs, and prior to that, held general management positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology, a publicly traded division of Genzyme, and corporate vice president of Genzyme Corporation. Ms. Maderis has been a member of several boards, and currently serves on The Mayor’s Biotech Advisory Council of San Francisco, as well as the HBS Healthcare Initiative board.
Ms. Maderis received a B.S. degree in business from the University of California at Berkeley and an M.B.A. from Harvard Business School.
Mr. Zavodnick has served as a director of NovaBay since May 2016. Mr. Zavodnick is currently the Chief Commercial Officer and President, Aesthetics & Therapeutics of Revance, Inc. since September 2017. Prior to joining Revance, Inc., Mr. Zavodnick has served as President, International at ZELTIQ Aesthetics, Inc. from January 2016 to August 2017. Previously, Mr. Zavodnick served as President and General Manager of North America at Galderma, having worked there from May 2012 to January 2016. From January 2004 to July 2012, Mr. Zavodnick worked at Alcon, eventually serving as the President of Alcon China and Mongolia. Mr. Zavodnick also serves the board of Allurion Technologies, and the Children’s Skin Disease Foundation.
Mr. Zavodnick received a bachelor’s degree from Rutgers University and an M.B.A. degree from the University of Texas at Dallas.
MIJIA WU (BOB WU)
Since June 2008, Mr. Wu has been the Managing Director of China Kington, an affiliated entity of China Kington Investment Co. Ltd., which acted as the sole
placement agent for a $6.86 million private placement of NovaBay common stock and warrants to purchase common stock in May 2015. Concurrently, he has served as the Managing Director of Shanghai Ceton Investment Management Co. Ltd. Since October 2013, he has also been the Non-Executive Director of China Pioneer Pharmaceutical Holdings Ltd. (“Pioneer”). Previously, he served as Director at UBS AG, Hong Kong Branch, in 2007 and Vice President of BNP Paribas Hong Kong from 2005 to 2006. He was also the Assistant Vice President at ABN AMRO Bank (China) Co., Ltd. from 2002 to 2005. All told, Mr. Wu brings over 10 years of experience in finance and investment to the Board.
He holds a Master in Business Administration from Manchester Business School, University of Manchester and an Executive Master in Business Administration from Cheung Kong Graduate School of Business.
XIAOYAN LIU (LAWRENCE LIU)
Mr. Liu has served as a director of NovaBay since March 2018. Mr. Lawrence Liu is currently the Joint Chief Operating Officer & Head of Direct Investment of OP Financial Investments Limited in Hong Kong (“OP Financial”). Mr. Lawrence Liu is particularly experienced in cross-border direct investment. Prior to that, Mr. Lawrence Liu was the Investment Director of China-ASEAN Capital Advisory Co., Ltd. from 2014 to 2015. From 2011 to 2014, Mr. Lawrence Liu served as the Head of Project Finance & Syndication Department (EMEA Coverage) and from 2006 to 2011 as the Head of M&A and Structured Finance Department, Corporate Banking, both at the Bank of China Limited in London. From 2002 to 2006, Mr. Lawrence Liu served as the Key Account Manager, Corporate Banking at the Bank of China Limited in Beijing.
Mr. Liu received an Executive MBA (Investment & Strategy) from CASS Business School in London and a bachelor’s degree in Business and Economics from the University of International Business and Economics in Beijing, China.